Finance News – Novo Nordisk
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The departure of the CEO at the Danish pharmaceutical company is expected to impact investor confidence as the firm navigates increased market rivalry and aims to sustain its finan...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Here’s how much extra weight is lost with Zepbound over Wegovy
A recent comparison of two popular weight-loss medications highlighted a measurable difference in effectiveness, potentially influencing market share and revenue for the companies...
Read Full Article →Novo Nordisk cuts guidance as weight-loss drug market competition grows
Novo Nordisk's quarterly results surpassed expectations, yet the company reduced its future growth projections due to increasing rivalry within the weight management pharmaceutical...
Read Full Article →Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.
Despite lowering its profit forecast, Novo Nordisk’s stock value is increasing, reflecting investor confidence amid a challenging market environment this year.
Read Full Article →Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
Novo Nordisk's reduced earnings outlook reflects challenges in maintaining sales momentum for its obesity treatment, as competitive pressures from US rivals increasingly impact its...
Read Full Article →Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit bea...
Despite reporting higher-than-anticipated first-quarter earnings, Novo Nordisk adjusted its 2025 revenue outlook downward due to slower demand for Wegovy, impacting overall financi...
Read Full Article →CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Starting July 1, Caremark will prioritize Wegovy on its formulary, improving accessibility for patients on its drug plans and potentially increasing the treatment's market presence...
Read Full Article →